Medexus Pharmaceuticals Inc reported significant earnings misses, raising concerns about its financial trajectory.
In its latest earnings report for the fiscal period ending June 30, 2026, Medexus Pharmaceuticals Inc (MDP.TO) delivered an EPS of $0.0279, falling short of the estimated $0.11 by 74.64%. This disappointing performance comes on the heels of a mixed earnings history, where the company has seen two beats out of the last four quarters. Let's delve deeper into the specifics of the earnings report and what it means for investors.
Recent earnings trend
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
-1.20%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 37.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+37.3% Upside
Current Price
C$4.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
41.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.26 | C$4.44 – C$6.23 |
| 60 trading days | C$5.59 | C$4.40 – C$7.10 |
| 90 trading days | C$5.93 | C$4.42 – C$7.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-10 | 0.0279 | 0.1100 | -74.6% |
| 2026-03-31 | 2026-06-25 | -0.1135 | 0.0100 | -1235.0% |
| 2025-12-31 | 2026-02-11 | 0.0034 | -0.0400 | +108.5% |
| 2025-09-30 | 2025-11-12 | -0.0100 | -0.0700 | +85.7% |
| 2025-06-30 | 2025-08-12 | 0.0100 | -0.0800 | +112.5% |
| 2025-03-31 | 2025-06-26 | -0.0259 | -0.1300 | +80.1% |
Advertisement
Investor takeaway: The substantial earnings miss may raise red flags for investors, particularly given the company's recent track record of volatility. Potential investors should weigh the implications of this performance against the backdrop of Medexus's ongoing product developments and market positioning.
EPS Misses by 74.64%
Medexus's EPS of $0.0279 starkly contrasted with the consensus estimate of $0.11, marking a significant surprise that could impact investor sentiment.
Bull case
Despite the recent earnings miss, Medexus has shown some resilience. The company has performed well with certain products, especially GRAFAPEX. Analysts are still optimistic, with an average price target of C$6.81, suggesting there could be potential upside from current levels.
Bear case
The significant earnings miss raises concerns about the company's financial health. The volatility in earnings and the recent public offering might indicate challenges in generating consistent profits moving forward.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
